180 related articles for article (PubMed ID: 8664132)
21. Endovascular lung perfusion using high-dose cisplatin: uptake and DNA adduct formation in an animal model.
Brown DB; Ma MK; Battafarano RJ; Naidu S; Pluim D; Zamboni WC; McLeod HL
Oncol Rep; 2004 Jan; 11(1):237-43. PubMed ID: 14654932
[TBL] [Abstract][Full Text] [Related]
22. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.
Reed E; Parker RJ; Gill I; Bicher A; Dabholkar M; Vionnet JA; Bostick-Bruton F; Tarone R; Muggia FM
Cancer Res; 1993 Aug; 53(16):3694-9. PubMed ID: 8339278
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
Hoebers FJ; Pluim D; Hart AA; Verheij M; Balm AJ; Fons G; Rasch CR; Schellens JH; Stalpers LJ; Bartelink H; Begg AC
Cancer Chemother Pharmacol; 2008 May; 61(6):1075-81. PubMed ID: 17639394
[TBL] [Abstract][Full Text] [Related]
24. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.
Reed E; Ozols RF; Tarone R; Yuspa SH; Poirier MC
Proc Natl Acad Sci U S A; 1987 Jul; 84(14):5024-8. PubMed ID: 3110781
[TBL] [Abstract][Full Text] [Related]
25. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
26. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival.
Fisch MJ; Howard KL; Einhorn LH; Sledge GW
Clin Cancer Res; 1996 Jun; 2(6):1063-6. PubMed ID: 9816268
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Souid AK; Dubowy RL; Blaney SM; Hershon L; Sullivan J; McLeod WD; Bernstein ML
Clin Cancer Res; 2003 Feb; 9(2):703-10. PubMed ID: 12576438
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
29. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
de Jongh FE; Verweij J; Loos WJ; de Wit R; de Jonge MJ; Planting AS; Nooter K; Stoter G; Sparreboom A
J Clin Oncol; 2001 Sep; 19(17):3733-9. PubMed ID: 11533095
[TBL] [Abstract][Full Text] [Related]
30. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
31. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors.
Dominici C; Petrucci F; Caroli S; Alimonti A; Clerico A; Castello MA
J Clin Oncol; 1989 Jan; 7(1):100-7. PubMed ID: 2909663
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin-DNA adducts and protein-bound platinum in blood of testicular cancer patients.
Boffetta P; Fichtinger-Schepman AM; Weiderpass E; van Dijk-Knijnenburg HC; Stoter G; van Oosterom AT; Keizer HJ; Fosså SD; Kaldor J; Roy P
Anticancer Drugs; 1998 Feb; 9(2):125-9. PubMed ID: 9510497
[TBL] [Abstract][Full Text] [Related]
33. DNA adduct formation and T-lymphocyte mutation induction in F344 rats implanted with tumorigenic doses of 1,6-dinitropyrene.
Smith BA; Fullerton NF; Heflich RH; Beland FA
Cancer Res; 1995 Jun; 55(11):2316-24. PubMed ID: 7757982
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
Reed E; Ostchega Y; Steinberg SM; Yuspa SH; Young RC; Ozols RF; Poirier MC
Cancer Res; 1990 Apr; 50(8):2256-60. PubMed ID: 2180564
[TBL] [Abstract][Full Text] [Related]
35. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
[TBL] [Abstract][Full Text] [Related]
36. Effects of cisplatin and amphotericin B on DNA adduct formation and toxicity in malignant glioma and normal tissues in rat.
Bergström P; Johnsson A; Cavallin-Ståhl E; Bergenheim T; Henriksson R
Eur J Cancer; 1997 Jan; 33(1):153-9. PubMed ID: 9071915
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
38. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin DNA adduct detection and depurination measured by 32P DNA radiolabeling and two-dimensional thin-layer chromatography: a time and concentration study.
Farah N; Dresner HS; Searles KJ; Winiarsky R; Moosikasuwan M; Cajigas A; Hahm S; Steinberg JJ
Cancer Invest; 2000; 18(4):314-26. PubMed ID: 10808367
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
